Registration Opening Soon for BOS Events 2025!

Dates for BOS Events 2025 are confirmed as 11th and 12th June for BOS Basel 2025 and 25th and 26th November for BOS Manchester 2025. Please find further details outlining provisional floor plans and pricing options at the event links provided. Note that we plan to open for registrations on Monday 4th November at 09.00 GMT.

The focus of these events is partnerships in R&D outsourcing with the primary scope being development-stage CMC outsourcing of Small Molecules, Biologics and New Therapeutic Entities.

We continue to evaluate the opportunity for digital events and resources, please look out for an announcement soon on this. We look forward to welcoming you and your colleagues to BOS Events! Please contact the Bio2Business team for further details.

Follow us on LinkedIn to see our latest announcements


Featured Company (BOS Basel 2024)

Logo for LAURUS SYNTHESIS PRIVATE LIMITED
LAURUS SYNTHESIS PRIVATE LIMITED
• Providing end-to-end CDMO Services to Pharma (Human and Animal Health) and Crop Protection Industries
• Drug Substance Development in our R&D facility with more than 1000 scientists. Supported by latest lab scale process equipment and analytical instruments
• Drug Product Development integrating...
View profile

Featured Speaker (BOS Manchester 2024)

photo of Dr Dr Yasunori Abe

Observations and Challenges in Global Registration of a New Anti-Cancer Drug.

Dr Yasunori Abe, Manager, Taiho Pharmaceutical Co., Ltd.

ABSTRACT: Taiho Pharmaceutical Company, part of the Otsuka Group of Companies, is a mid-sized pharmaceutical company headquartered in Tokyo. The company is expanding its Global reach through a developing pipeline of innovative oncology products. Lytgobi® (Futibatinib), which is the subject of this presentation, is the first product that Taiho has marketed in the 3 major territories of the USA, Japan, and EU.

Our presentation will reflect on some observations and challenges we faced in achieving this global resignation. The first part will focus on the control of two Critical Quality Attributes... Click here to Read More